A5067941434- Cystic Fibrosis Research Advances
- Neonatal Respiratory Health Research
- Tracheal and airway disorders
- Asthma and respiratory diseases
- Inhalation and Respiratory Drug Delivery
Duke Medical Center
2023
Nationwide Children's Hospital
2009
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators promote robust clinical improvements in people with cystic (pwCF) qualifying genotypes [1, 2]. A triple combination therapy consisting of two CFTR folding correctors (elexacaftor and tezacaftor) plus potentiator ivacaftor, referred to as ETI, has been approved by the FDA European agencies (<https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis>,...
Cystic Fibrosis (CF) is the most common lethal genetic disorder in Caucasian population, affecting about 30,000 people United States. It results inflammation, hence thickening of airway (AW) walls. has been demonstrated that AW inflammation begins early life producing structural damage. Because this damage can be present patients who are relatively asymptomatic, lung disease progress insidiously. High-resolution computed tomographic imaging also shown AWs infants and young children with CF...